Developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system


Voyager Therapeutics (NASDAQ: VYGR) is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.


Year Invested: 2014
Location: Cambridge, Mass.
Visit: www.voyagertherapeutics.com

Recent News

March 14, 2018
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

March 9, 2018
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease

February 27, 2018
Voyager Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results and Corporate Highlights Conference Call

Read More News

Associated Team Members

Mark Levin
Partner

Philip Reilly, M.D., J.D.
Venture Partner